Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome

Haematologica. 2004 Feb;89(2):236-7.

Authors

Giovanni Martinelli¹, Michele Malagola, Emanuela Ottaviani, Gianantonio Rosti, Elena Trabacchi, Michele Baccarani

Affiliation

¹ Institute of Hematology and Medical Oncology "L and A Seràgnoli", University of Bologna, Italy.

PMID: 15003901

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Benzamides
Enzyme Inhibitors / pharmacology
Enzyme Inhibitors / therapeutic use*
Exons / genetics
HL-60 Cells
Humans
Hypereosinophilic Syndrome / drug therapy*
Hypereosinophilic Syndrome / genetics
Imatinib Mesylate
Male
Oncogene Proteins, Fusion / antagonists & inhibitors*
Oncogene Proteins, Fusion / genetics
Piperazines / pharmacology
Piperazines / therapeutic use*
Pyrimidines / pharmacology
Pyrimidines / therapeutic use*
RNA Splicing
RNA, Messenger / genetics
Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors*
Receptor, Platelet-Derived Growth Factor alpha / genetics*
Remission Induction
mRNA Cleavage and Polyadenylation Factors / antagonists & inhibitors*
mRNA Cleavage and Polyadenylation Factors / genetics*

Substances

Benzamides
Enzyme Inhibitors
FIP1L1 protein, human
Oncogene Proteins, Fusion
Piperazines
Pyrimidines
RNA, Messenger
mRNA Cleavage and Polyadenylation Factors
Imatinib Mesylate
FIP1L1-PDGFRA fusion protein, human
Receptor, Platelet-Derived Growth Factor alpha